Concepedia

Flavia Adler

FA

Statistics

Publications

3

Citations

243

H-Index

3

Active since

2019

Affiliations

Novartis (Switzerland)(Current)

Novartis Institutes for BioMedical Research

American Institutes for Research

Flavia Adler is an author at Novartis (Switzerland) specializing in pharmacology, cancer pharmacology, and drug discovery.

Publications per year

2019–2023

3

Publications

3

Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4

Robin A. Fairhurst, Thomas Knoepfel, Nicole Buschmann et al. · Journal of Medicinal Chemistry · 2020 · 113 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer

Andreas Weiss, Flavia Adler, Alexandra Buhles et al. · Molecular Cancer Therapeutics · 2019 · 102 citations

Medicine, Oncology, Pharmacology +16

CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer

Anirudh Prahallad, Andreas Weiss, Hans Voshol et al. · Cancer Research · 2023 · 28 citations · Full text

Medicine, Oncology, Pharmacology +13

1–3 of 3